Tech

“We’re not doing 30 bets a year”: Vijay Pandeon betting small after running $4 billion at a16z

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thi

This story summarizes reporting from TechCrunch. Read the original for full context. Wire items stay in our news sitemap for seven days. Editorial policy.

Global — Connie Loizos